Skip to main content
SpringerLink
Log in

Tumorspezifische Therapien und ihr Einsatz in der Palliativmedizin

Implications of modern anticancer therapies for palliative care concepts

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Schmerz Aims and scope Submit manuscript

Zusammenfassung

In der modernen Onkologie vollziehen sich zurzeit weitreichende Veränderungen, die sich einerseits in konzeptuellen Entwicklungen und erweiterten Möglichkeiten, Tumortherapien nach individuellem Risiko und tumorbiologischen Aspekten zu individualisieren, andererseits in einer Vielzahl neuer tumorspezifischer Substanzen widerspiegeln. Diese Entwicklungen haben auch Auswirkungen auf die Behandlung von Patienten mit inkurablen, fortgeschrittenen Tumorerkrankungen, bei denen Schmerztherapie und Symptomkontrolle, Lebensqualität und andere palliativmedizinische Therapieziele im Vordergrund stehen. Für die Tumorschmerztherapie und die Palliativmedizin können Kenntnisse moderner onkologischer Therapien hilfreich sein, da diese das Potenzial haben, die mit der Grunderkrankung einhergehende Symptomlast zu reduzieren, und – nach sorgfältiger, interdisziplinärer Abwägung von deren möglichen Risiken, Nebenwirkungen und erhofftem Nutzen – in palliativmedizinische Behandlungskonzepte integriert werden können.

Abstract

In modern oncology, paradigmatic developments can be witnessed with respect to conceptual strategies and to individualized diagnostics and treatment approaches, but foremost with respect to the amazing number of new anticancer substances available. These developments will certainly influence the care of patients suffering from incurable and advanced cancer, where pain therapy and symptom control, quality of life and other intentions of palliative care are urgent. For cancer pain therapy and palliative care, knowledge about these developments may be helpful not only with respect to interdisciplinary decision making, but also for thoroughly balancing risks, side effects and benefits of oncological interventions that have the potential to stabilize disease progression and thereby reduce symptom intensity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. World Health Organisation (WHO) (1996) Cancer pain relief, with a guide to opioid availability, 2. Aufl. WHO, Geneva

  2. Sobrero A, Andretta V (2008) Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer. Onkologie 31:224–225

    Article  PubMed  Google Scholar 

  3. Medicines in development for cancer. http://www.phrma.org/medicines_in_development_for_cancer/

  4. Colomer R, Alba E, Gonzales-Martin A et al (2010) Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol 21:195–198

    Article  CAS  PubMed  Google Scholar 

  5. Winer E, Gralow J, Diller L et al (2009) Clinical advances 2008: major research advances in cancer treatment, prevention and screening – a report from the American Society of Medical Oncology. J Clin Oncol 27:812–826

    Article  PubMed  Google Scholar 

  6. Bruzzi P, DelMastro L, Sormani MP et al (2005) Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23:5117–5125

    Article  PubMed  Google Scholar 

  7. Buyse M, Thirion P, Carlson RW et al (2000) Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: meta-analysis. Meta-Analysis Group in Cancer. Lancet 356:373–378

    Article  CAS  PubMed  Google Scholar 

  8. Hotta K, Kiura K, Fujiwara Y et al (2009) Association between incremental gains in the objective response rate and serviva improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 20:829–834

    Article  CAS  PubMed  Google Scholar 

  9. Ferraldeschi R, Lorigan P (2009) Extensive-disease small-cell lung cancer – moving beyond response rate? Ann Oncol 20:801–802

    Article  CAS  PubMed  Google Scholar 

  10. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 335(26):2733–2743

    Article  Google Scholar 

  11. Braun S, Marth C (2004) Circulating tumor cells in metastatic breast cancer – toward individualized treatment? N Engl J Med 351:824–825

    Article  CAS  PubMed  Google Scholar 

  12. Dahut WL, Scripture C, Posadas E et al (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14(1):209–214

    Article  CAS  PubMed  Google Scholar 

  13. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965–3970

    Article  PubMed  Google Scholar 

  14. Bördlein-Wahl I, Hilpert F, Kohlmann T (2009) Therapiebeurteilung aus Patientensicht – patient reported outcomes. Onkologie 32(Suppl 1):18–20

    Article  PubMed  Google Scholar 

  15. Burris H, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413

    CAS  PubMed  Google Scholar 

  16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  17. Ohorodynk P, Eisenhauer EA, Booth CM (2009) Clinical benefit in oncology trials: is this a patient-centered or tumor-centered end-point? Eur J Cancer 45:2249–2252

    Article  Google Scholar 

  18. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372:1809–1818

    Article  CAS  PubMed  Google Scholar 

  19. Tassinari D, Drudi F, Lazzari-Agli L et al (2010) Second-line treatments of advanced non-small cell lung cancer: new evidence for clinical practice. Ann Oncol 21:428–429

    Article  CAS  PubMed  Google Scholar 

  20. Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada clinical trials group study BR.21. J Clin Oncol 24(24):3831–3837

    Article  CAS  PubMed  Google Scholar 

  21. Berry DL, Moinpour CM, Jiang CS et al (2006) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24(18):2828–2835

    Article  CAS  PubMed  Google Scholar 

  22. Caraceni A, DeDonno F (1998) Analgesic effects of chemotherapy? J Clin Oncol 16(2):803

    CAS  PubMed  Google Scholar 

  23. Siena S, Crinò L, Danova M et al (2010) Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 21:655–661

    Article  CAS  PubMed  Google Scholar 

  24. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guidelines (version 1.1.). Eur J Cancer 45:228–247. http://www.eortc.be/recist/documents/RECISTGuidelines.pdf

    Google Scholar 

  25. Benjamin RS, Choi H, Macapinlac HA et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764

    Article  PubMed  Google Scholar 

  26. Choi H, Charnsangavey C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of a new computed tomography response criteria. J Clin Oncol 25(13):1753–1759

    Article  PubMed  Google Scholar 

  27. Junker A (2009) Personalisierte Krebsmedizin – immer erfolgreicher umsetzbar. Dtsch Ärztebl 30:1285–1286

    Google Scholar 

  28. Sarmiento R, Gasparini G (2008) Antiangiogenic metronomic chemotherapy. Onkologie 31:161–162

    Article  PubMed  Google Scholar 

  29. Görn M, Habermann C, Anige M et al (2008) A pilot study of docetaxel and trofosfamide as second-line „metronomic“ chemotherapy in the treatment of metastatic non-small cell lung cancer. Onkologie 31:185–189

    PubMed  Google Scholar 

  30. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967

    Article  CAS  PubMed  Google Scholar 

  31. Lim WT, McLeod HL (2004) Should screening for DPD deficiency be mandatory before 5-FU exposure? Onkologie 27:531

    Article  PubMed  Google Scholar 

  32. Helbekkmo N, Aasebo U, Sundstrom SH et al (2008) Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 62:253–260

    Article  PubMed  Google Scholar 

  33. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel – carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542–2550

    Article  CAS  PubMed  Google Scholar 

  34. Earle CC, Landrum MB et al (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26(23):3860–3866

    Article  PubMed  Google Scholar 

  35. Bauer AW (2003) Futility-Debatte in der Onkologie – ein ethisches und rechtliches Problem. Onkologe 9:1325–1334

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abteilung Palliativmedizin, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland

    B. Alt-Epping & F. Nauck

Authors
  1. B. Alt-Epping
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Nauck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Alt-Epping.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alt-Epping, B., Nauck, F. Tumorspezifische Therapien und ihr Einsatz in der Palliativmedizin. Schmerz 24, 633–641 (2010). https://doi.org/10.1007/s00482-010-0940-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00482-010-0940-0

Schlüsselwörter

Keywords

Search

Navigation